VANCOUVER, April 4 /PRNewswire-FirstCall/ - Angiotech Pharmaceuticals, Inc. (NASDAQ: ANPI, TSX: ANP), a global specialty pharmaceutical and medical device company, announced today that the first New Zealand patient was treated with Cook Medical Inc.'s Zilver(R) PTX(TM) drug-eluting peripheral stent in December 2007. A second patient was treated in February 2008. The Zilver PTX is the world's first drug-eluting stent for peripheral arterial disease (PAD) and was recently released for sale in certain regions worldwide including New Zealand.
Under the terms of its 1997 License Agreement with Cook, Angiotech is entitled to receive royalty payments upon the commercial sale of paclitaxel-eluting peripheral vascular stent products, including the Zilver PTX.
"Building on the success of our paclitaxel-eluting coronary stents, it is rewarding to see how our technology continues to be leveraged in other vascular indications. We hope that the Zilver PTX may provide a more long term treatment option for patients who suffer from peripheral arterial disease," said Dr. William Hunter, President and CEO of Angiotech.
The Zilver PTX is currently undergoing multiple clinical trials in the U.S., Japan, and the EU to assess product safety and efficacy.
About Zilver PTX
Cook Medical's Zilver PTX, a self-expanding nitinol stent, uses a proprietary, polymer-free technology to coat the device with paclitaxel, an antiproliferative drug that has been used successfully to reduce the risk of renarrowing of arteries following angioplasty. In many cases, PAD patients who have been treated with balloon angioplasty and stenting experience restenosis, or renarrowing of the arteries, over time and must undergo more invasive treatment such as bypass surgery to reopen the arteries. The Zilver PTX trials will determine whether the combination of the stent and paclitaxel will keep arteries open over time.
About Peripheral Artery Disease (PAD)
Peripheral Artery Disease (PAD) affects blood vessels that lead from the heart to other areas of the body, such as the legs, feet and kidneys. When the blood vessels become blocked due to the build-up of fatty deposits, blood circulation is restricted. Untreated, PAD results in pain when walking and can lead to gangrene and amputation.
Note on Forward Looking Statements
Statements contained in this press release that are not based on
historical fact, including without limitation statements containing the
words "believes," "may," "plans," "will," "estimate," "continue,"
"anticipates," "intends," "expects" and similar expressions, constitute
"forward-looking statements" within the meaning of the U.S. Private
Securities Litigation Reform Act of 1995 and constitute "forward-looking
information" within the meaning of applicable Canadian securities laws. All
such statements are made pursuant to the "safe harbor" provisions of
applicable securities legislation. Forward-looking statements may involve,
but are not limited to, comments with respect to our strategies or future
actions, our targets, expectations for our financial condition and the
results of, or outlook for, our operations, research development and
product and drug development. Such forward-looking statements involve known
and unknown risks, uncertainties and other factors that may cause the
actual results, events or developments to be materially different from any
future results, events or developments expressed or implied by such
forward-looking statements. Many such risks, uncertainties and other
factors are taken into account as part of our assumptions underlying these
forward-looking statements and include, among others, the following:
general economic and business conditions, both nationally and in the
regions in which we operate; market demand; technological changes that
could impact our existing products or our ability to develop and
commercialize future products; competition; existing governmental
regulations and changes in, or the failure to comply with, governmental
regulations; adverse results or unexpected delays in drug discovery and
clinical development processes; decisions, and the timing of decisions,
made by health regulatory agencies regarding approval of our technology and
products; the requirement for substantial funding to conduct research and
development and to expand commercialization activities or consummate
acquisitions; the accuracy of our estimations of the size of the market,
and the potential market, for our products in specific disease areas; sales
numbers and future guidance publicly provided by Boston Scientific
Corporation regarding sales of their paclitaxel-eluting coronary stent
products; and any other factors that may affect performance. In addition,
our business is subject to certain operating risks that may cause the
actual results expressed or implied by the forward-looking statements in
this report to differ materially from our actual results. These operating
risks include: our ability to attract and retain qualified personnel; our
ability to successfully complete preclinical and clinical development of
our products; changes in business strategy or development plans; our
failure to obtain patent protection for discoveries; loss of patent
protection resulting from third party challenges to our patents;
commercialization limitations imposed by patents owned or controlled by
third parties; our ability to obtain rights to technology from licensors;
liability for patent claims and other claims asserted against us; our
ability to obtain and enforce timely patent and other intellectual property
protection for our technology and products; the ability to enter into, and
to maintain, corporate alliances relating to the development and
commercialization of our technology and products; market acceptance of our
technology and products; our ability to successfully manufacture, market
and sell our products; the ability of Boston Scientific Corporation to
successfully manufacture, market and sell their paclitaxel-eluting coronary
stent products; the continued availability of capital to finance our
activities; our ability to achieve the financial benefits expected as a
result of the acquisition of American Medical Instruments Holdings, Inc.
("AMI"); and any other factors referenced in our annual information form
and other filings with the applicable Canadian securities regulatory
authorities or the SEC. Given these uncertainties, assumptions and risk
factors, readers are cautioned not to place undue reliance on such
forward-looking statements. We disclaim any obligation to update any such
factors or to publicly announce the result of any revisions to any of the
forward-looking statements contained in this press release to reflect
future results, events or developments.
Zilver(R) PTX(TM) are trademarks of Cook Medical.
Angiotech Pharmaceuticals, Inc. is a global specialty pharmaceutical and medical device company with over 1,500 dedicated employees. Angiotech discovers, develops and markets innovative treatment solutions for diseases or complications associated with medical device implants, surgical interventions and acute injury. To find out more about Angiotech (NASDAQ: ANPI, TSX: ANP), please visit our website at http://www.angiotech.com.
CONTACT: Deirdre Neary, Angiotech Pharmaceuticals, Inc., (604) 222-7056, firstname.lastname@example.org
|SOURCE Angiotech Pharmaceuticals, Inc.|
Copyright©2008 PR Newswire.
All rights reserved